Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Zodasiran in Homozygous Familial Hypercholesterolemia (YOSEMITE)
jRCT2061250081Phase 3Active, not recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- May 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, open-label trial of zodasiran in familial hypercholesterolemia (FH) (3 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Percent Change from Baseline to Month 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C). Started May 2026; status: active, not recruiting.
02
Drugs
zodasiran
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on jRCT2061250081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250081.